TREATMENT OPTIMIZATION IN ALK-POSITIVE METASTATIC NON-SMALL CELL LUNG
PFIZER, S.A
Object
Topic: Oncology.
Destination: Projects in scope include creation and deployment of educational content or programs. Projects that will be considered for Pfizer support will focus on the following educational topics:
- Latest clinical data updates relevant to the treatment of patients with advanced or metastatic ALK-positive NSCLC.
- Elements of optimal clinical management of these patients, e.g., mitigation of adverse events, and dose modification.
- Role of the caregiver in clinical management, e.g., dose modification/compliance, adverse event identification.
Budget: Up to $250,000/project
Duration: Not indicated.